<DOC>
	<DOCNO>NCT00560144</DOCNO>
	<brief_summary>This 3 arm study determine dose R1507 achieve mean drug exposure child adolescent advance solid tumor equivalent exposure achieve adult recommend dose 9mg/kg/week . It also determine maximum tolerate dose ( appropriate ) pharmacokinetic profile R1507 . Groups patient sequentially enrol one 3 dose level ( 3,9mg/kg PK-derived dose , exceed 16 mg/kg ) R1507 administer weekly intravenous infusion.An expand cohort patient enrol optimal dose/MTD . The anticipated time study treatment disease progression dose limit toxicity , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study R1507 Children Adolescents With Advanced Solid Tumors .</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>pediatric patient age 217 year age ; histologically confirm solid tumor ; cancer relapse , fail respond , curative therapy , potentially curative treatment option available . treatment corticosteroid within past 2 week ; current past use antiIGF1R antibody ; current treatment immunosuppressive agent ; patient diabetes mellitus ; know HIV hepatitis B C ; hypersensitivity component R1507 monoclonal antibody .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>